JBIOJade Biosciences, Inc.
$14.42+94% 1Y
$14.42
$7.6152 weeks$26.85
JBIO as reported
- Net income
- −$153M
Net income · +67% year on year · trailing twelve months to Q2 2026
- EPS
- −$1.92
EPS · −90% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$153M | +67% | Q2 2026 |
| EPS | −$1.92 | −90% | Q2 2026 |
| ROE | −43% | n/a | Q2 2026 |
| ROA | −40% | n/a | Q2 2026 |
| Free cash flow | −$57M | n/a | Q4 2023 · 10 quarters behind |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Jade Biosciences, Inc. (JBIO) · Net incomeNet incomeJade Biosciences, Inc. (JBIO)
On our screens:Most shorted stocks